Kelly L. Stratton, MD, presented “Early Stage Testicular Cancer Update” during the 5th Annual Oklahoma Prostate & Urologic Cancers Symposium on September 13th, 2019 in Oklahoma City, Oklahoma.

How to cite: Stratton, Kelly L. Early Stage Testicular Cancer Update” September 13th, 2019. Accessed Dec 2024. https://grandroundsinurology.com/early-stage-testicular-cancer-update​/

Early Stage Testicular Cancer Update – Summary:

Kelly L. Stratton, MD, an assistant professor of Urologic Oncology in the University of Oklahoma Department of Urology, discusses newly released guidelines for early-stage testicular cancer. He goes on to describe how these guidelines, provided by the American Urological Association, were designed to provide doctors with guidance on the diagnosis and treatment of the disease. He then goes on to discuss how to identify patients who would benefit from treatment post-orchiectomy, as well as how to develop a follow-up strategy in those patients who are candidates for surveillance.

About The 5th Annual Prostate & Urologic Cancer Symposium:

The Prostate & Urologic Cancers Symposium is held through the University of Oklahoma and the Stephenson Cancer Center to provide new insights in the treatment of prostate and urologic cancers. This single-day program consists of lectures and case discussions highlighting a multidisciplinary approach to urologic cancer care and integration of new technology in the evaluation and treatment of patients with prostate and/or urologic cancers. Dr. Stratton presented this lecture during the 5th iteration of this summit in 2019. 

For further educational activities from this conference, visit our collection page.

ABOUT THE AUTHOR

+ posts

Kelly L. Stratton, MD, is an Assistant Professor of Urologic Oncology in the University of Oklahoma (OU) Department of Urology in Oklahoma City. Prior to joining the OU Urology team in 2014, he completed his fellowship training in the Department of Surgery (Urology Service) at Memorial Sloan-Kettering Cancer Center in New York and his residency at Vanderbilt University Medical Center Department of Urology. He completed his MD with special distinction at the OU College of Medicine in 2007.

Dr. Stratton brings experience with state-of-the-art imaging for the diagnosis and treatment of prostate cancer. He is interested in the application of new technology capable of blending MRI images with real-time ultrasound to improve prostate biopsy and cancer detection. Using these techniques, he can assist patients considering prostate cancer treatment options including those who are candidates for active surveillance. He also utilizes genomic testing to help provide personalized treatment plans for patients diagnosed with urologic cancer. Dr. Stratton is involved in several clinical trials that provide the most advanced treatment options currently available.

Dr. Stratton holds memberships in the American Society of Clinical Oncology, the Society of Urologic Oncology, and the American Urological Association. He serves as a reviewer for the Journal of Urology and was recently recognized as the Best Reviewer in Oncology. He is a contributor to Practical Reviews in Urology.. Dr. Stratton is also an author of numerous publications and abstracts, as well as of a book chapter on inherited predisposition to cancer for the American Cancer Society.